Tavis Read1,2,3, Michael Lonne2, David S Sparks2, Michael David4,5, Michael Wagels1,2, Helmut Schaider6, H Peter Soyer6, B Mark Smithers1,2. 1. Queensland Melanoma Project, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 2. The University of Queensland, Faculty of Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 3. Griffith University, School of Medicine, Gold Coast, Queensland, Australia. 4. The University of Queensland, School of Health and Rehabilitation Sciences, Brisbane, Queensland, Australia. 5. The University of Newcastle, School of Medicine and Public Health, Newcastle, New South Wales, Australia. 6. The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.
Abstract
BACKGROUND AND OBJECTIVES: In-transit melanoma (ITM) metastases present a therapeutic challenge and management decisions can be difficult. There are multiple treatments available, with differing efficacy, and supported by different levels of evidence. The primary objective was to perform a systematic review and where suitable, a meta-analysis of the literature reporting on the use of locoregional treatments for the management of ITM. METHODS: An independent review was conducted including a comprehensive search of the National Library of Medicine using PubMed, MEDLINE, Embase, and Cochrane Library databases. Key data were tabulated, synthesized and pooled to calculate relevant weighted effect sizes for each therapy using random-effect models. The statistical heterogeneity was calculated using the Higgins' method. RESULTS: Of the initial 32 612 articles identified, 57 original articles satisfied eligibility criteria. Eight treatment modalities were identified comprising: amputation (7); hyperthermic isolated limb perfusion (15); isolated limb infusion (8); carbon dioxide laser (9); PV-10 intralesional therapy (5); IL-2 intralesional therapy (8); imiquimod (7); diphenylcyclopropenone (3). Only amputation and topical imiquimod were suitable for formal meta-analysis. CONCLUSIONS: All of the assessed therapies have significant selection bias. Variable levels of evidence support the ongoing use of locoregional treatments and these may significantly improve disease-free survival.
BACKGROUND AND OBJECTIVES: In-transit melanoma (ITM) metastases present a therapeutic challenge and management decisions can be difficult. There are multiple treatments available, with differing efficacy, and supported by different levels of evidence. The primary objective was to perform a systematic review and where suitable, a meta-analysis of the literature reporting on the use of locoregional treatments for the management of ITM. METHODS: An independent review was conducted including a comprehensive search of the National Library of Medicine using PubMed, MEDLINE, Embase, and Cochrane Library databases. Key data were tabulated, synthesized and pooled to calculate relevant weighted effect sizes for each therapy using random-effect models. The statistical heterogeneity was calculated using the Higgins' method. RESULTS: Of the initial 32 612 articles identified, 57 original articles satisfied eligibility criteria. Eight treatment modalities were identified comprising: amputation (7); hyperthermic isolated limb perfusion (15); isolated limb infusion (8); carbon dioxide laser (9); PV-10 intralesional therapy (5); IL-2 intralesional therapy (8); imiquimod (7); diphenylcyclopropenone (3). Only amputation and topical imiquimod were suitable for formal meta-analysis. CONCLUSIONS: All of the assessed therapies have significant selection bias. Variable levels of evidence support the ongoing use of locoregional treatments and these may significantly improve disease-free survival.
Authors: Maryam Pourmaleki; Caitlin J Jones; Charlotte E Ariyan; Zheng Zeng; Mono Pirun; Daniel A Navarrete; Yanyun Li; Mianlei Zhang; Subhiksha Nandakumar; Carl Campos; Saad Nadeem; David S Klimstra; Claire F Temple-Oberle; Thomas Brenn; Evan J Lipson; Kara M Schenk; Julie E Stein; Janis M Taube; Michael G White; Raymond Traweek; Jennifer A Wargo; John M Kirkwood; Billel Gasmi; Stephanie L Goff; Alex D Corwin; Elizabeth McDonough; Fiona Ginty; Margaret K Callahan; Andrea Schietinger; Nicholas D Socci; Ingo K Mellinghoff; Travis J Hollmann Journal: Cancer Immunol Res Date: 2022-03-01 Impact factor: 12.020
Authors: Anna K Lawless; David J Coker; Serigne N Lo; Tasnia Ahmed; Richard A Scolyer; Sydney Ch'ng; Omgo E Nieweg; Kerwin Shannon; Andrew Spillane; Jonathan R Stretch; John F Thompson; Robyn P M Saw Journal: Ann Surg Oncol Date: 2022-06-30 Impact factor: 4.339
Authors: Emilia Nan Tie; Julia Lai-Kwon; Michael Alexander Rtshiladze; Lumine Na; James Bozzi; Tavis Read; Victoria Atkinson; George Au-Yeung; Georgina V Long; Grant A McArthur; Shahneen Sandhu; Robyn Saw; Euan Walpole; Alexander Menzies; Mark Smithers; David E Gyorki Journal: J Immunother Cancer Date: 2020-05 Impact factor: 13.751